Figure 1
From: Securin promotes the identification of favourable outcome in invasive breast cancer
Kaplan–Meier curves of breast cancer survival based on securin immunohistochemistry in 310 breast cancer patients. Securin immunohistochemistry (positivity <1.5% (A) vs ⩾1.5% (B) of cancer cell nuclei) distinguishes patients with a different outcome of disease (P=0.004).
